Pharmaxis Presents New Analyses of Pooled Cystic Fibrosis Data at European Meeting

18th Jun 13

Release Date: 18/06/2013 12:00am

Pharmaceutical company Pharmaxis (ASX:PXS) has  presented  new analyses from the pooled data of its two large scale phase 3 studies in cystic fibrosis illustrating the longer term benefits for patients who respond to Bronchitol® and the product’s value to healthcare systems. The presentation has been made at this year’s European Cystic Fibrosis Society conference in Lisbon, Portugal where it was awarded “Best Poster”.

Read full media release - pdf

Categories: News and Media